← All trials
NCT03200080
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 18, 2017
- Primary completion
- Nov 28, 2017
- Completion date
- Nov 28, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 26
- Arms / groups
- 6 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Biotie TherapiesLead sponsor
- Acorda TherapeuticsCollaborator
- INC ResearchOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.